These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19556961)

  • 1. Tumor biomarkers in melanoma.
    Ugurel S; Utikal J; Becker JC
    Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
    Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
    Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating biomarkers in malignant melanoma.
    Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
    Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
    Shiiyama R; Fukushima S; Jinnin M; Yamashita J; Miyashita A; Nakahara S; Kogi A; Aoi J; Masuguchi S; Inoue Y; Ihn H
    Melanoma Res; 2013 Oct; 23(5):366-72. PubMed ID: 23863473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.
    Utikal J; Schadendorf D; Ugurel S
    Arch Dermatol Res; 2007 Mar; 298(10):469-77. PubMed ID: 17221215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant melanoma--markers for progression and prognosis in malignant melanoma.
    Geilen CC; Georgieva J; Milling A; Farthmann B
    Front Radiat Ther Oncol; 2006; 39():120-126. PubMed ID: 16394675
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma.
    Solassol J; Du-Thanh A; Maudelonde T; Guillot B
    Int J Biol Markers; 2011; 26(2):82-7. PubMed ID: 21607923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnosis of melanoma-have we arrived?
    Bordelon JR; Grichnik JM
    Dermatol Ther; 2015; 28(6):405. PubMed ID: 26031627
    [No Abstract]   [Full Text] [Related]  

  • 9. Current staging and prognostic factors in melanoma.
    Bartlett EK; Karakousis GC
    Surg Oncol Clin N Am; 2015 Apr; 24(2):215-27. PubMed ID: 25769707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular classification and markers of malignant melanoma].
    Tímár J; Hársing J; Somlai B
    Magy Onkol; 2013 Jun; 57(2):73-8. PubMed ID: 23795351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.
    Bougnoux AC; Solassol J
    Clin Biochem; 2013 Apr; 46(6):518-23. PubMed ID: 23262402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance.
    Nezos A; Lembessis P; Sourla A; Pissimissis N; Gogas H; Koutsilieris M
    Clin Chem Lab Med; 2009; 47(1):1-11. PubMed ID: 19055471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
    Van Laar R; Lincoln M; Van Laar B
    Br J Cancer; 2018 Mar; 118(6):857-866. PubMed ID: 29360813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New prognostic factors and developing therapy of cutaneous melanoma.
    Vihinen PP; Pyrhönen SO; Kähäri VM
    Ann Med; 2003; 35(2):66-78. PubMed ID: 12795336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.
    Tian R; Liu T; Qiao L; Gao M; Li J
    Int J Clin Exp Pathol; 2015; 8(3):3097-103. PubMed ID: 26045823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker.
    Fischer GM; Carapeto FCL; Joon AY; Haydu LE; Chen H; Wang F; Van Arnam JS; McQuade JL; Wani K; Kirkwood JM; Thompson JF; Tetzlaff MT; Lazar AJ; Tawbi HA; Gershenwald JE; Scolyer RA; Long GV; Davies MA
    Cancer Med; 2020 Nov; 9(22):8650-8661. PubMed ID: 33016647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers.
    Hyams DM; Cook RW; Buzaid AC
    J Surg Oncol; 2019 Jan; 119(2):175-186. PubMed ID: 30548543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.
    Zhao Y; Schaafsma E; Gorlov IP; Hernando E; Thomas NE; Shen R; Turk MJ; Berwick M; Amos CI; Cheng C
    Mol Cancer Res; 2019 Jan; 17(1):109-119. PubMed ID: 30171176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
    Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
    Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene expression profiling in melanoma: past results and future potential.
    Knackstedt RW; Knackstedt T; Gastman B
    Future Oncol; 2019 Mar; 15(7):791-800. PubMed ID: 30453756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.